Cure Alzheimer's Fund Cure Alzheimer's Fund

Philip Scheltens, M.D., Ph.D.

Professor of Cognitive Neurology and Director of the Alzheimer Center at Amsterdam University Medical Centers

Prof. dr. Philip Scheltens studied at the VU University Amsterdam, Netherlands, gaining his MD in 1984, and Ph.D. (Magnetic Resonance Imaging in Alzheimer’s disease) in 1993. Clinical residencies in neurosurgery at the Municipal Hospital Slotervaart, and at the VU University Medical Centre, Amsterdam, supported his academic development.

Dr. Scheltens is Professor of Cognitive Neurology and Director of the Alzheimer Center at Amsterdam University Medical Centers. His main clinical and research interests are Alzheimer’s disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national PI for over 35 studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 68 Ph.D. theses have appeared since then. In 2013 he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as chair of the board since then. He is also the co-editor-in-chief of Alzheimer’s Research & Therapy, one of the leading journals in this field.

He has authored over 1013 peer-reviewed papers and > 75 book chapters. Dr. Scheltens co-edited the books on Magnetic Resonance in Dementia and Neuroimaging in dementia (Springer), Neuroimaging in Dementia (Springer) and co-edited the book on Functional Magnetic Resonance Imaging: Clinical Applications (Oxford University Press). In 2011, he was elected as member of the Royal Dutch Academy of Arts and Sciences (KNAW) and served as Secretary General until 2020. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research.

He is co-leading and participating in various EU projects, such as IMI-EPAD, IMI-AMYPAD, EMIF-AD, RADAR-AD, Euro-Fingers.

 

 

 

Related Research:

Understanding and Mimicking the Biological Effects of the Phospholipase C-gamma-2 P522R Variant That Protects Against Alzheimer’s Disease Rik van der Kant Philip Scheltens 2021-01-29

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Project Description Researchers Funding
Understanding and Mimicking the Biological Effects of the Phospholipase C-gamma-2 P522R Variant That Protects Against Alzheimer’s Disease 2020, 2022

$345,588.75

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Koetsier, J., Cavill, R., Reijnders, R., Harvey, J., Homann, J., … Dobricic, V., … Scheltens, P., … Zetterberg, H., … Lill, C. L., Bertram, L., … Pishva, E. Blood-based multivariate methylation risk score for cognitive impairment and dementia, Alzheimer's & Dementia, August 28, 2024, Read More

Homann, J., Osburg, T., Ohlei, O., Dobricic, V., Deecke, L., Bos, I., Vandenberghe, R., Gabel, S., Scheltens, P., Teunissen, C. E., Engelborghs, S., Frisoni, G., Blin, O., Richardson, J. C., Bordet, R., Lleó, A., Alcolea, D., Popp, J., Clark, C., Peyratout, G., Martinez-Lage, P., Tainta, M., Dobson, R.J.B., Legido-Quigley, C., Sleegers, K., Van Broeckhoven, C., Wittig, M., Franke, A., Lill, C.M., Blennow, K., Zetterberg, H., Lovestone, S., Streffer, J., Kate, M., Vos, S. J. B., Barkhof, F., Visser, P. J., & Bertram, L. Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset, Frontiers in Aging Neuroscience, March 21, 2022, Read More

Neumann, A., Ohlei, O., Küçükali, F., Bos, I. J., Timsina, J., Vos, S., Prokopenko, D., Tijms, B. M., Andreasson, U., Blennow, K., Vandenberghe, R., Scheltens, P., Teunissen, C. E., Engelborghs, S., Frisoni, G. B., Blin, O., Richardson, J. C., Bordet, R., Lleó, A., Alcolea, D., … EMIF-AD & ADNI study group Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning, Genome Medicine, October 4, 2023, Read More

Back to Our Researchers